These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 24170235)
1. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Sorli C; Warren M; Oyer D; Mersebach H; Johansen T; Gough SC Drugs Aging; 2013 Dec; 30(12):1009-18. PubMed ID: 24170235 [TBL] [Abstract][Full Text] [Related]
2. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654 [TBL] [Abstract][Full Text] [Related]
3. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R; Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318 [TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727 [TBL] [Abstract][Full Text] [Related]
6. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. Einhorn D; Handelsman Y; Bode BW; Endahl LA; Mersebach H; King AB Endocr Pract; 2015 Aug; 21(8):917-26. PubMed ID: 26121451 [TBL] [Abstract][Full Text] [Related]
7. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344 [TBL] [Abstract][Full Text] [Related]
8. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Norwood P; Chen R; Jaeckel E; Lingvay I; Jarlov H; Lehmann L; Heller S Diabetes Obes Metab; 2017 Nov; 19(11):1562-1569. PubMed ID: 28417535 [TBL] [Abstract][Full Text] [Related]
9. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM. Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798 [TBL] [Abstract][Full Text] [Related]
10. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus. Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113 [TBL] [Abstract][Full Text] [Related]
12. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753 [TBL] [Abstract][Full Text] [Related]
13. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934 [TBL] [Abstract][Full Text] [Related]
14. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial. Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456 [TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial]. Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034 [No Abstract] [Full Text] [Related]
16. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. Koehler G; Heller S; Korsatko S; Roepstorff C; Rasmussen S; Haahr H; Pieber TR Diabetologia; 2014 Jan; 57(1):40-9. PubMed ID: 24057153 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC; J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185 [TBL] [Abstract][Full Text] [Related]
18. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes. Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408 [TBL] [Abstract][Full Text] [Related]
19. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR; Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443 [TBL] [Abstract][Full Text] [Related]
20. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study. Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]